7-30633830-G-A

Variant names:

Variant summary

Our verdict is Benign. The variant received -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BS1BS2

The NM_002047.4(GARS1):c.2190G>A(p.Glu730Glu) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000772 in 1,595,330 control chromosomes in the GnomAD database, including 8 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0041 ( 5 hom., cov: 31)

Exomes 𝑓: 0.00042 ( 3 hom. )

Consequence

GARS1
NM_002047.4 synonymous

Scores

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: 3.48

Publications

1 publications found

Variant links:

Genes affected

GARS1 (HGNC:4162): (glycyl-tRNA synthetase 1) This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The encoded enzyme is an (alpha)2 dimer which belongs to the class II family of tRNA synthetases. It has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]

GARS1 Gene-Disease associations (from GenCC):

Charcot-Marie-Tooth disease type 2D
Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), Orphanet
neuronopathy, distal hereditary motor, type 5A
Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Illumina, Laboratory for Molecular Medicine
spinal muscular atrophy, infantile, James type
Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics

GARS1 links:

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -19 ACMG points.

BP4

Computational evidence support a benign effect (BayesDel_noAF=-0.41).

BP6

Variant 7-30633830-G-A is Benign according to our data. Variant chr7-30633830-G-A is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 377913.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

BP7

Synonymous conserved (PhyloP=3.47 with no splicing effect.

BS1

Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.0041 (619/151086) while in subpopulation AFR AF = 0.0143 (591/41228). AF 95% confidence interval is 0.0134. There are 5 homozygotes in GnomAd4. There are 300 alleles in the male GnomAd4 subpopulation. Median coverage is 31. This position passed quality control check.

BS2

High AC in GnomAd4 at 619 AD gene.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
GARS1	NM_002047.4 link	c.2190G>A	p.Glu730Glu	synonymous_variant	Exon 17 of 17	ENST00000389266.8	NP_002038.2
GARS1	NM_001316772.1 link	c.2028G>A	p.Glu676Glu	synonymous_variant	Exon 17 of 17		NP_001303701.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein
GARS1	ENST00000389266.8 link	c.2190G>A	p.Glu730Glu	synonymous_variant	Exon 17 of 17	1	NM_002047.4	ENSP00000373918.3
GARS1	ENST00000675651.1 link	c.2208G>A	p.Glu736Glu	synonymous_variant	Exon 17 of 17			ENSP00000502513.1
GARS1	ENST00000675810.1 link	c.2088G>A	p.Glu696Glu	synonymous_variant	Exon 16 of 16			ENSP00000502743.1
GARS1	ENST00000675693.1 link	c.2022G>A	p.Glu674Glu	synonymous_variant	Exon 18 of 18			ENSP00000502174.1
GARS1	ENST00000675051.1 link	c.1989G>A	p.Glu663Glu	synonymous_variant	Exon 17 of 17			ENSP00000502296.1
GARS1	ENST00000674815.1 link	c.1821G>A	p.Glu607Glu	synonymous_variant	Exon 17 of 17			ENSP00000502799.1
GARS1	ENST00000674851.1 link	c.1821G>A	p.Glu607Glu	synonymous_variant	Exon 18 of 18			ENSP00000502451.1
GARS1	ENST00000444666.6 link	n.*611G>A		non_coding_transcript_exon_variant	Exon 18 of 18	3		ENSP00000415447.2
GARS1	ENST00000674616.1 link	n.*1904G>A		non_coding_transcript_exon_variant	Exon 18 of 18			ENSP00000502408.1
GARS1	ENST00000674643.1 link	n.*1995G>A		non_coding_transcript_exon_variant	Exon 17 of 17			ENSP00000501636.1
GARS1	ENST00000674737.1 link	n.*1528G>A		non_coding_transcript_exon_variant	Exon 18 of 18			ENSP00000502464.1
GARS1	ENST00000674807.1 link	n.*463G>A		non_coding_transcript_exon_variant	Exon 16 of 16			ENSP00000502814.1
GARS1	ENST00000675529.1 link	n.*2060G>A		non_coding_transcript_exon_variant	Exon 18 of 18			ENSP00000501655.1
GARS1	ENST00000675859.1 link	n.*369G>A		non_coding_transcript_exon_variant	Exon 15 of 15			ENSP00000502033.1
GARS1	ENST00000676088.1 link	n.*2132G>A		non_coding_transcript_exon_variant	Exon 19 of 19			ENSP00000501884.1
GARS1	ENST00000676140.1 link	n.*1135G>A		non_coding_transcript_exon_variant	Exon 17 of 17			ENSP00000502571.1
GARS1	ENST00000676164.1 link	n.*1641G>A		non_coding_transcript_exon_variant	Exon 17 of 17			ENSP00000501986.1
GARS1	ENST00000676210.1 link	n.*1479G>A		non_coding_transcript_exon_variant	Exon 18 of 18			ENSP00000502373.1
GARS1	ENST00000676259.1 link	n.*1622G>A		non_coding_transcript_exon_variant	Exon 17 of 17			ENSP00000501980.1
GARS1	ENST00000676403.1 link	n.*275G>A		non_coding_transcript_exon_variant	Exon 16 of 16			ENSP00000502681.1
GARS1	ENST00000444666.6 link	n.*611G>A		3_prime_UTR_variant	Exon 18 of 18	3		ENSP00000415447.2
GARS1	ENST00000674616.1 link	n.*1904G>A		3_prime_UTR_variant	Exon 18 of 18			ENSP00000502408.1
GARS1	ENST00000674643.1 link	n.*1995G>A		3_prime_UTR_variant	Exon 17 of 17			ENSP00000501636.1
GARS1	ENST00000674737.1 link	n.*1528G>A		3_prime_UTR_variant	Exon 18 of 18			ENSP00000502464.1
GARS1	ENST00000674807.1 link	n.*463G>A		3_prime_UTR_variant	Exon 16 of 16			ENSP00000502814.1
GARS1	ENST00000675529.1 link	n.*2060G>A		3_prime_UTR_variant	Exon 18 of 18			ENSP00000501655.1
GARS1	ENST00000675859.1 link	n.*369G>A		3_prime_UTR_variant	Exon 15 of 15			ENSP00000502033.1
GARS1	ENST00000676088.1 link	n.*2132G>A		3_prime_UTR_variant	Exon 19 of 19			ENSP00000501884.1
GARS1	ENST00000676140.1 link	n.*1135G>A		3_prime_UTR_variant	Exon 17 of 17			ENSP00000502571.1
GARS1	ENST00000676164.1 link	n.*1641G>A		3_prime_UTR_variant	Exon 17 of 17			ENSP00000501986.1
GARS1	ENST00000676210.1 link	n.*1479G>A		3_prime_UTR_variant	Exon 18 of 18			ENSP00000502373.1
GARS1	ENST00000676259.1 link	n.*1622G>A		3_prime_UTR_variant	Exon 17 of 17			ENSP00000501980.1
GARS1	ENST00000676403.1 link	n.*275G>A		3_prime_UTR_variant	Exon 16 of 16			ENSP00000502681.1

Frequencies

GnomAD3 genomes

AF:

0.00410

AC:

619

AN:

150958

Hom.:

Cov.:

show subpopulations

Gnomad AFR

AF:

0.0144

Gnomad AMI

AF:

0.00

Gnomad AMR

AF:

0.00112

Gnomad ASJ

AF:

0.00

Gnomad EAS

AF:

0.00

Gnomad SAS

AF:

0.00

Gnomad FIN

AF:

0.00

Gnomad MID

AF:

0.00

Gnomad NFE

AF:

0.000118

Gnomad OTH

AF:

0.00144

GnomAD2 exomes

AF:

0.00102

AC:

255

AN:

249482

AF XY:

0.000879

show subpopulations

Gnomad AFR exome

AF:

0.0137

Gnomad AMR exome

AF:

0.000898

Gnomad ASJ exome

AF:

0.00

Gnomad EAS exome

AF:

0.00

Gnomad FIN exome

AF:

0.0000464

Gnomad NFE exome

AF:

0.0000353

Gnomad OTH exome

AF:

0.000825

GnomAD4 exome

AF:

0.000424

AC:

613

AN:

1444244

Hom.:

Cov.:

AF XY:

0.000384

AC XY:

276

AN XY:

718396

show subpopulations

African (AFR)

AF:

0.0146

AC:

478

AN:

32770

American (AMR)

AF:

0.000817

AC:

AN:

44090

Ashkenazi Jewish (ASJ)

AF:

0.00

AC:

AN:

25402

East Asian (EAS)

AF:

0.00

AC:

AN:

38510

South Asian (SAS)

AF:

0.0000465

AC:

AN:

86094

European-Finnish (FIN)

AF:

0.0000392

AC:

AN:

51048

Middle Eastern (MID)

AF:

0.000529

AC:

AN:

5672

European-Non Finnish (NFE)

AF:

0.0000381

AC:

AN:

1101436

Other (OTH)

AF:

0.000811

AC:

AN:

59222

Allele Balance Distribution

Red line indicates average allele balance

Average allele balance: 0.455

Heterozygous variant carriers

130

163

0.00

0.20

0.40

0.60

0.80

0.95

Allele balance

Age Distribution

Exome Het

Exome Hom

Variant carriers

100

<30

30-35

35-40

40-45

45-50

50-55

55-60

60-65

65-70

70-75

75-80

>80

Age

GnomAD4 genome

AF:

0.00410

AC:

619

AN:

151086

Hom.:

Cov.:

AF XY:

0.00406

AC XY:

300

AN XY:

73802

show subpopulations

African (AFR)

AF:

0.0143

AC:

591

AN:

41228

American (AMR)

AF:

0.00112

AC:

AN:

15190

Ashkenazi Jewish (ASJ)

AF:

0.00

AC:

AN:

3470

East Asian (EAS)

AF:

0.00

AC:

AN:

5070

South Asian (SAS)

AF:

0.00

AC:

AN:

4672

European-Finnish (FIN)

AF:

0.00

AC:

AN:

10334

Middle Eastern (MID)

AF:

0.00

AC:

AN:

294

European-Non Finnish (NFE)

AF:

0.000118

AC:

AN:

67806

Other (OTH)

AF:

0.00142

AC:

AN:

2110

Allele Balance Distribution

Red line indicates average allele balance

Average allele balance: 0.508

Heterozygous variant carriers

118

148

0.00

0.20

0.40

0.60

0.80

0.95

Allele balance

Age Distribution

Genome Het

Genome Hom

Variant carriers

<30

30-35

35-40

40-45

45-50

50-55

55-60

60-65

65-70

70-75

75-80

>80

Age

Alfa

AF:

0.00177

Hom.:

Bravo

AF:

0.00443

Asia WGS

AF:

0.000289

AC:

AN:

3478

EpiCase

AF:

0.0000545

EpiControl

AF:

0.0000593

ClinVar

Significance: Benign/Likely benign

Submissions summary: Benign:6

Revision: criteria provided, multiple submitters, no conflicts

LINK: link

Submissions by phenotype

not specified

Benign:2

Apr 26, 2016

GeneDx

Significance:Benign

Review Status:criteria provided, single submitter

Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.

Jul 11, 2019

Ambry Genetics

Significance:Likely benign

Review Status:criteria provided, single submitter

Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.

not provided

Benign:2

Dec 12, 2017

Athena Diagnostics

Significance:Benign

Review Status:criteria provided, single submitter

Collection Method:clinical testing

Mar 31, 2022

ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories

Significance:Benign

Review Status:criteria provided, single submitter

Collection Method:clinical testing

Charcot-Marie-Tooth disease type 2

Benign:1

Jan 06, 2025

Labcorp Genetics (formerly Invitae), Labcorp

Significance:Benign

Review Status:criteria provided, single submitter

Collection Method:clinical testing

GARS1-related disorder

Benign:1

Jul 08, 2019

PreventionGenetics, part of Exact Sciences

Significance:Benign

Review Status:no assertion criteria provided

Collection Method:clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).

Computational scores

Source: dbNSFP v4.3

Name

Calibrated prediction

Score

Prediction

BayesDel_noAF

Benign

-0.41

CADD

Benign

7.2

(source)

DANN

Benign

0.52

PhyloP100

3.5

Mutation Taster

=100/0

polymorphism

(source)

Splicing

Name

Calibrated prediction

Score

Prediction

SpliceAI score (max)

0.0

Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.

Variant summary

Frequency

Consequence

Scores

Clinical Significance

Conservation

Publications

ACMG classification

Transcripts

RefSeq

Ensembl

Frequencies

Age Distribution

Age Distribution

ClinVar

Submissions by phenotype

Computational scores

Splicing

Publications

Other links and lift over